kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human KLK-6 Protein, His Tag, 100µg  

Recombinant human KLK-6 Protein, His Tag, 100µg

Recombinant human Kallikrein 6 / KLK6 (rhKLK6) Glu17-Lys244 was produced in human HEK293 cells, His Tag

recombinant human protein, KLK6, KLK-6, Kallikrein-6, Kallikrein6, Kallikrein

More details


Availability: within 7 days

312,00 €

Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins. In humans, tissue kallikrein-related peptidases (KLKs) encode a family of fifteen closely related serine proteases. Kallikreins are responsible for the co-ordination of various physiological functions including blood pressure, semen liquefaction and skin desquamation. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. 
Kallikrein-6 (KLK6) also known as Bssp, Klk7, MGC9355, PRSS18, PRSS9, SP59 and hK6. KLK6 is one of the fifteen kallikrein subfamily members, and is regulated by steroid hormones. In tissue culture, KLK6 has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer\'s disease. The prior studies indicate KLK6 is elevated at sites of central nervous system (CNS) inflammation and which shows regulated expression with T cell activation. Notably, KLK6 is also elevated in the serum of multiple sclerosis (MS) patients. KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. KLK6 are also associated with neuronal plasticity in the central nervous system.[1-4]

Recombinant human KLK6 protein (rhKLK6) Glu17-Lys244 (Accession # (AAH15525) fused with 6x his at the C-terminus was produced in human HEK293 cells.

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 18.0 kDa (mature form) or 26.0 kDa (pro form). The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per 1 μg by the LAL method.

>95% as determined by SDS-PAGE. All lots are greater than 95% pure.

Bulk protein in a 0.22 μm filtered solution of PBS, pH 7.4 and delivered as liquid formulation or lyophilized powder.Normally trehalose and mannitol are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).


(1) Tamura H, et al., 2006, J Physiol 1;570 (3): 541–51.
(2) Scarisbrick IA, et al., 2001, PLoS One., 28;6(3):e18376.
(3) Ashby EL., et al., 2010, Brain Res, 1363:1-10.
(4) Kim JT, et al., 2011, Cancer., 117(12):2608-19.